RSI reading of 27.97 suggests selling pressure is exhausting, coinciding with analysts agreeing on better earnings for Spero Therapeutics.
1 report, 1 independent
Updated Aug 19
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
RSI reading of 27.97 suggests selling pressure is exhausting, coinciding with analysts agreeing on better earnings for Spero Therapeutics.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Spero Therapeutics (United States)
company in Cambridge, United States
Nothing else this week.
Coverage
Newest first; wire copies grouped- ZacksDown 17.7% in 4 Weeks, Here's Why Spero Therapeutics (SPRO) Looks Ripe for a Turnaround A downtrend has been apparent in Spero Therapeutics, Inc. (SPRO) lately with too much selling pressure. The sto